EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting KRAS in colorectal cancer immunotherapy: rationale, challenges and future directions

Gongmin Zhu, Lijiao Pei, Di Ye, Qiulin Tang, Huanji Xu, Feng Bi

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2025

DOI: 10.1016/j.bbcan.2025.189382 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025. Verfasst von Gongmin Zhu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Abdominal Cancer, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hosp…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 114 Literaturangaben. Gefördert von: Science and Technology Department of Sichuan Province, China Postdoctoral Science Foundation, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kirsten rat sarcoma (KRAS) is frequently mutated in colorectal cancer (CRC). In recent years, mutant KRAS has shed its "undruggable" label, with two clinically approved inhibitors now available. Besides aberrantly activating intrinsic tumor cell growth signaling, oncogenic KRAS contributes to the development of an immunosuppressive tumor microenvironment (TME), especially in CRC. This suggests KRAS inhibition may enhance responsiveness to immunotherapy, supporting the rationale for combining mutant KRAS inhibitors with immune checkpoint blockade (ICB). Mutant KRAS is considered as an ideal immunological target. Emerging therapeutics, including vaccines, TCR-T cell therapies and antibodies, are being developed to treat KRAS-mutant CRC patients that leverage peptides or peptide/major histocompatibility complex class I (MHC-I) complexes generated by mutant KRAS. Here, we provide an overview of targeting mutant KRAS in CRC immunotherapy, discussing challenges and future directions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsProto-Oncogene Proteins p21(ras)ImmunotherapyImmune Checkpoint InhibitorsHumansTumor MicroenvironmentMutationAnimalsMolecular Targeted Therapy

Stichwörter der Autor:innen

Colorectal cancerImmunotherapyKRAS inhibitorsKRAS mutationsTumor microenvironment

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Abdominal Cancer, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China.
  • Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China.
  • Division of Abdominal Cancer, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China. Ele…

Förderung

  • Science and Technology Department of Sichuan Province
  • China Postdoctoral Science Foundation
  • Sichuan University
  • Sichuan University West China Hospital
  • National Natural Science Foundation of China

Zitieren

APA

Zhu, G., Pei, L., Ye, D., Tang, Q., Xu, H., & Bi, F. (2025). Targeting KRAS in colorectal cancer immunotherapy: rationale, challenges and future directions. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2025.189382

Vancouver

Zhu G, Pei L, Ye D, Tang Q, Xu H, Bi F. Targeting KRAS in colorectal cancer immunotherapy: rationale, challenges and future directions. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025. doi:10.1016/j.bbcan.2025.189382

BibTeX
@article{Zhu2025,
  author = {Zhu, Gongmin and Pei, Lijiao and Ye, Di and Tang, Qiulin and Xu, Huanji and Bi, Feng},
  title = {Targeting KRAS in colorectal cancer immunotherapy: rationale, challenges and future directions},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2025},
  doi = {10.1016/j.bbcan.2025.189382}
}
Kostenlos starten →